Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03075553
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:44.364358+00:00
Published At
2020-04-21T00:00:00+00:00
Record Updated At
2020-04-21
Results Posted At
2020-04-21
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Blastic Plasmacytoid Dendritic Cell Neoplasm", "Hepatosplenic T-Cell Lymphoma", "HTLV-1 Infection", "NK-Cell Lymphoma, Unclassifiable", "Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative", "Recurrent Adult T-Cell Leukemia/Lymphoma", "Recurrent Anaplastic Large Cell Lymphoma", "Recurrent Angioimmunoblastic T-cell Lymphoma", "Recurrent Enteropathy-Associated T-Cell Lymphoma", "Recurrent Mycosis Fungoides", "Refractory Adult T-Cell Leukemia/Lymphoma", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Angioimmunoblastic T-cell Lymphoma", "Refractory Enteropathy-Associated T-Cell Lymphoma", "Refractory Mycosis Fungoides", "Refractory Nasal Type Extranodal NK/T-Cell Lymphoma", "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-04-21"
protocolSection.identificationModule.nctId
"NCT03075553"
protocolSection.identificationModule.officialTitle
"Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2020-04-21"

Study condition terms

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Hepatosplenic T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • HTLV-1 Infection (protocolSection.conditionsModule.conditions)
  • NK-Cell Lymphoma, Unclassifiable (protocolSection.conditionsModule.conditions)
  • Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative (protocolSection.conditionsModule.conditions)
  • Recurrent Adult T-Cell Leukemia/Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Angioimmunoblastic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Enteropathy-Associated T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mycosis Fungoides (protocolSection.conditionsModule.conditions)
  • Refractory Adult T-Cell Leukemia/Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Angioimmunoblastic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Enteropathy-Associated T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Mycosis Fungoides (protocolSection.conditionsModule.conditions)
  • Refractory Nasal Type Extranodal NK/T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.